查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1604757

自體免疫疾病治療藥物市場：按產品、應用分類 - 全球預測 2025-2030

Autoimmune Disease Therapeutics Market by Product (Diagnostic Equipment, Drugs), Application (Localized Autoimmune Diseases, Systemic Autoimmune Diseases) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，自體免疫疾病治療市值為1,989.9億美元，預計2024年將達到2,145.4億美元，複合年成長率為7.90%，到2030年將達到3,390億美元。

自體免疫疾病治療市場包括旨在管理和減輕自體免疫疾病的治療方法和藥物，在這種疾病中，人體的免疫系統錯誤地攻擊自身組織。類風濕性關節炎、狼瘡和多發性硬化症等自體免疫疾病的日益流行推動了對這些療法的需求，這些疾病需要複雜的醫療干預措施。這些療法的用途包括生物製藥、免疫抑制劑和單株抗體，它們針對免疫系統的特定成分來緩解症狀並改善患者的治療結果。最終用途包括專門治療自體免疫疾病的醫院、診所和專科中心。

主要市場統計
基準年[2023] 1989.9億美元
預計年份 [2024] 2145.4億美元
預測年份 [2030] 3390億美元
複合年成長率（%） 7.90%

影響該市場的主要成長要素包括生物技術的進步、對自體免疫疾病的認知不斷提高以及新療法研發投資的增加。個人化醫療的興起也推動了成長，因為治療方法可以根據個人的基因特徵進行客製化。新興市場存在著機遇，醫療基礎設施得到改善，對可近治療方法的需求不斷成長。製藥公司和研究機構之間的合作研究可以帶來突破性的治療方法。公司必須專注於提高藥物的功效和安全性，以獲得市場佔有率。

然而，挑戰仍然存在，包括高昂的治療成本、嚴格的法律規範以及與長期使用相關的潛在副作用。此外，對疾病機制的了解有限也阻礙了突破。創新應集中在基因治療和開發更精確、副作用更少的生技藥品。遠端醫療位治療等數位健康解決方案可以改善患者監測和治療依從性。

總體而言，市場充滿活力，預計將在技術進步和加強醫療保健政策的支持下實現強勁成長。為了實現永續的業務成長，公司必須利用創新來提高治療效果、成本效益和患者的生活品質，同時應對監管複雜性和科學挑戰。認知並整合精準醫療和數位健康的趨勢可以推動市場進一步擴張和創新。

市場動態：揭示快速發展的自體免疫疾病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變自體免疫疾病治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球自體免疫疾病流行
    • 醫療基礎設施快速完善，意識層級不斷提高
    • 實驗室自動化以促進一些自體免疫診斷測試
  • 市場限制因素
    • 高成本且治療結果不確定性
  • 市場機會
    • 增加政府機構和非營利組織的資金
    • 自體免疫疾病標靶治療的出現
  • 市場挑戰
    • 自體免疫疾病免疫治療的副作用

波特五力：駕馭自體免疫疾病藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解自體免疫疾病治療市場的外部影響

外部宏觀環境因素在塑造自體免疫疾病治療市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解自體免疫疾病治療藥物市場的競爭狀況

對自體免疫疾病治療藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣自體免疫疾病治療市場供應商的績效評估

FPNV定位矩陣是評估自體免疫疾病治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，為自體免疫疾病治療藥物市場的成功指明道路

對於旨在加強其在全球市場的影響力的公司來說，對自體免疫疾病治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球自體免疫疾病盛行率增加
      • 醫療基礎設施的快速改善和病患意識的提高
      • 實驗室自動化促進多種自體免疫診斷測試
    • 抑制因素
      • 治療費用高，治療效果不確定。
    • 機會
      • 增加政府機構和非營利組織的資金
      • 自體免疫疾病標靶治療的出現
    • 任務
      • 自體免疫疾病免疫治療的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章自體免疫疾病治療藥物市場：依產品

  • 診斷設備
  • 藥物
    • 胺基或5-ASA
    • 蒽甙
    • Avonex
    • Betaseron
    • 卡利泊三烯
    • 科帕松
    • 皮質類固醇
    • 糖皮質激素
    • 羥氯喹
    • 胺基甲基葉酸
    • 非類固醇消炎劑
    • Rebif

第7章自體免疫疾病治療藥物市場：依應用分類

  • 局部自體免疫疾病
  • 系統性自體免疫疾病

第8章北美和南美自體免疫疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區自體免疫疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲自體免疫疾病治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA
Product Code: MRR-030C42D3EDB7

The Autoimmune Disease Therapeutics Market was valued at USD 198.99 billion in 2023, expected to reach USD 214.54 billion in 2024, and is projected to grow at a CAGR of 7.90%, to USD 339.00 billion by 2030.

The Autoimmune Disease Therapeutics market encompasses treatments and pharmaceuticals aimed at managing and mitigating autoimmune disorders, where the body's immune system mistakenly attacks its own tissues. The necessity for these therapeutics is driven by the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis, demanding advanced medical interventions. Application of these therapeutics ranges from biologics and immunosuppressants to monoclonal antibodies, targeting specific components of the immune system to alleviate symptoms and improve patient outcomes. End-use involves hospitals, clinics, and specialty centers dedicated to managing autoimmune conditions.

KEY MARKET STATISTICS
Base Year [2023] USD 198.99 billion
Estimated Year [2024] USD 214.54 billion
Forecast Year [2030] USD 339.00 billion
CAGR (%) 7.90%

Key growth factors influencing this market include advancements in biotechnology, heightened awareness of autoimmune diseases, and increased investment in R&D for novel treatments. The rise in personalized medicine also propels growth, as therapies can be tailored to individual genetic profiles. Opportunities lie in emerging markets with growing healthcare infrastructure, coupled with the demand for accessible therapies. Collaborations between pharmaceutical companies and research institutions can lead to breakthrough treatments. Companies must focus on enhancing drug efficacy and safety profiles to capture market share.

However, challenges persist, such as high treatment costs, stringent regulatory frameworks, and potential side effects associated with long-term medication use. Limited understanding of disease mechanisms further hinders breakthrough advancements. Innovations should focus on gene therapies and the development of more precise biologics with fewer side effects. Digital health solutions like telemedicine and digital therapeutics can enhance patient monitoring and adherence to treatments.

Overall, the market is dynamic, with robust growth prospects supported by technological advances and healthcare policy enhancements. For sustainable business growth, companies must leverage innovations that improve therapeutic efficacy, cost-effectiveness, and patient quality of life while navigating regulatory complexities and scientific challenges. Recognizing and integrating trends in precision medicine and digital health can catalyze further market expansion and innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autoimmune Disease Therapeutics Market

The Autoimmune Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of autoimmune diseases across the globe
    • Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
    • Automation of laboratories to ease several autoimmune diagnostic tests
  • Market Restraints
    • High cost and uncertain outcomes of the treatment
  • Market Opportunities
    • Increasing funding by government associations and non-profit organizations
    • Emergence of target therapies for autoimmune disease
  • Market Challenges
    • Side effects of autoimmune diseases immunotherapy

Porter's Five Forces: A Strategic Tool for Navigating the Autoimmune Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autoimmune Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autoimmune Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autoimmune Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autoimmune Disease Therapeutics Market

A detailed market share analysis in the Autoimmune Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autoimmune Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autoimmune Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autoimmune Disease Therapeutics Market

A strategic analysis of the Autoimmune Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autoimmune Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Exagen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A..

Market Segmentation & Coverage

This research report categorizes the Autoimmune Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnostic Equipment and Drugs. The Drugs is further studied across Aminosalicylates or 5-ASA, Anthralin, Avonex, Betaseron, Calicipotriene, Copaxone, Corticosteriods, Glucocorticoids, Hydroxychloroquine, Methotrexate, Non-steroidal Anti-inflammatory Drugs, and Rebif.
  • Based on Application, market is studied across Localized Autoimmune Diseases and Systemic Autoimmune Diseases.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of autoimmune diseases across the globe
      • 5.1.1.2. Rapidly improvement in healthcare infrastructure coupled with rising patient awareness levels
      • 5.1.1.3. Automation of laboratories to ease several autoimmune diagnostic tests
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and uncertain outcomes of the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing funding by government associations and non-profit organizations
      • 5.1.3.2. Emergence of target therapies for autoimmune disease
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of autoimmune diseases immunotherapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Therapeutics Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnostic Equipment
  • 6.3. Drugs
    • 6.3.1. Aminosalicylates or 5-ASA
    • 6.3.2. Anthralin
    • 6.3.3. Avonex
    • 6.3.4. Betaseron
    • 6.3.5. Calicipotriene
    • 6.3.6. Copaxone
    • 6.3.7. Corticosteriods
    • 6.3.8. Glucocorticoids
    • 6.3.9. Hydroxychloroquine
    • 6.3.10. Methotrexate
    • 6.3.11. Non-steroidal Anti-inflammatory Drugs
    • 6.3.12. Rebif

7. Autoimmune Disease Therapeutics Market, by Application

  • 7.1. Introduction
  • 7.2. Localized Autoimmune Diseases
  • 7.3. Systemic Autoimmune Diseases

8. Americas Autoimmune Disease Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Autoimmune Disease Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioAgilytix Labs, LLC
  • 8. bioMerieux S.A.
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Exagen, Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Johnson & Johnson Services, Inc.
  • 15. Lupin Limited
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer, Inc.
  • 19. Sanofi S.A.
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Trinity Biotech PLC
  • 23. UCB S.A.
  • 24. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DIAGNOSTIC EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES OR 5-ASA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTHRALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AVONEX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BETASERON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CALICIPOTRIENE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COPAXONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTERIODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HYDROXYCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REBIF, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 50. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 90. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 154. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023